Bladder cancer

NEW --- Treatment approaches for patients diagnosed with (very) high-risk NMIBC

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Educational Objective: Identify the most appropriate treatment strategies for (very) high-risk non-muscle-invasive bladder cancer (NMIBC) in bacillus Calmette-Guérin (BCG)-naïve patients based on tumour pathology and patients’ individual characteristics and history.
Specialty: Urology, Medical oncology, Clinical oncology
Target Audience: Specialists (CME: basic, intermediate), Residents (senior)
Latest update: February 2025
Background:

The EAU and NCCN guidelines recommend stratifying patients with NMIBC into 4 risk groups (low, intermediate, high and very high) based on their probability of progression to muscle-invasive disease [1,2].

(Very) high-risk NMIBC according to the EAU and NCCN guidelines

*Clinical risk factors: age >70; multiple papillary tumours, tumour diameter >3 cm.

 

  1. Gontero P, Birtle A, Compérat E, et al. European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Update April 2024. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
  2. Flaig TW, Spiess PE, Abern M, et al. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: bladder cancer. Version 6.2024. Available at: https://www.nccn.org/guidelines/category_1